Nanjing Leads Biolabs Co Ltd (09887.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18

Key dataSep 18, 2026

OpenHKD 56.15

From 52W high−40.66%

Volume1.00M

Market capHKD 11.09B

P/E (TTM)—

P/S (TTM)41.0x

Div yield—

Key dataSep 18, 2026

Open

HKD 56.15

From 52W high

−40.66%

Volume

1.00M

Market cap

HKD 11.09B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−41.3x

P/E (TTM)

—

RSI (14)

36.3

MomentumView details →

1D Return

+0.00%

YTD Return

+9.31%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−41.3x

EV/Sales

37.2x

P/S (TTM)

41.0x

P/B (TTM)

10.2x

ProfitabilityView details →

Gross Margin

100.00%

Net Margin

−117.34%

EBITDA Margin

−90.04%

ROE (TTM)

−29.18%

ROA (TTM)

−17.65%

Asset Turnover

0.15x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

+349.62%

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

+0.00%

YTD Return

+9.31%

1Y Return

−12.62%

RSI (14)

36.3

vs 50D SMA

−13.13%

vs 200D SMA

−11.22%

Capital & dividendView details →

Debt/Equity

0.40x

Current Ratio

2.41x

Quick Ratio

2.29x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−HKD 0.17

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

231.45M

Net Income (TTM)

−271.59M

Op. CF (TTM)

0.00

Next earningsMar 29, 2027 →

Latest newsMore news →

Virelizhibo announced that its self-developed drug Weilixin (opartuzumab, PDL1/4-1BB bispecific antibody, LBL-024) has completed the safety run-in phase and entered the expansion stage of a Phase II clinical study for first-line treatment of locally advanced or metastatic esophageal squamous cell carcinoma (ESCC).27d ago

Similar companies

HBM Holdings Limited02142.HK 欧林生物688319.SH Axsome Therapeutics, Inc.AXSM Bio-Techne CorporationTECH Mabwell-b02493.HK 诺唯赞688105.SH Find similar companies →

Latest newsMore news →

Virelizhibo announced that its self-developed drug Weilixin (opartuzumab, PDL1/4-1BB bispecific antibody, LBL-024) has completed the safety run-in phase and entered the expansion stage of a Phase II clinical study for first-line treatment of locally advanced or metastatic esophageal squamous cell carcinoma (ESCC).27d ago